Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

41. Testing behavioral interventions to optimize participation in a population-based colorectal cancer screening program in Catalonia, Spain Full Text available with Trip Pro

Testing behavioral interventions to optimize participation in a population-based colorectal cancer screening program in Catalonia, Spain The aim of the study was to measure the effect of three cost-neutral behavioral interventions on participation compared to the standard invitation letter in a population-based colorectal cancer screening program in 2014. For that purpose, a four-arm randomized field trial was conducted among 5077 individuals aged 50 to 69 years. Over an 8-week period, each

2019 EvidenceUpdates

42. Making Patients Fit for Surgery: Introducing a Four Pillar Multimodal Prehabilitation Program in Colorectal Cancer. (Abstract)

Making Patients Fit for Surgery: Introducing a Four Pillar Multimodal Prehabilitation Program in Colorectal Cancer. Considering the relation between preoperative functional capacity and postoperative complications, enhancing patients' functional capacity before surgery with a prehabilitation program may facilitate faster recovery and improve quality of life. However, time before surgery is short, mandating a multimodal and high-intensity training approach. This study investigated feasibility (...) for colorectal cancer patients is feasible, safe, and effective. A randomized controlled trial (NTR5947) was initiated to determine whether prehabilitation may lower morbidity and mortality rates in colorectal surgery.

2019 American journal of physical medicine & rehabilitation Controlled trial quality: uncertain

43. The role of cell-free circulating DNA quantification in predicting recurrence of colorectal cancer: a systematic review and meta-analysis

The role of cell-free circulating DNA quantification in predicting recurrence of colorectal cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

44. Association between constipation duration and the risk of colorectal cancer: systematic review and meta-analysis

Association between constipation duration and the risk of colorectal cancer: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

45. Components of the full blood count (FBC) as risk factors for colorectal cancer detection: a systematic review

Components of the full blood count (FBC) as risk factors for colorectal cancer detection: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

46. Concurrent systematic chemotherapy and molecular targeted therapy for unresectable metastatic colorectal cancer : a systematic review

Concurrent systematic chemotherapy and molecular targeted therapy for unresectable metastatic colorectal cancer : a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

47. Risk factors, prevalence and risk of colorectal cancer among patients with young onset colonic adenomas

Risk factors, prevalence and risk of colorectal cancer among patients with young onset colonic adenomas Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

48. Pre-therapy weight loss and survival in colorectal cancer patients

Pre-therapy weight loss and survival in colorectal cancer patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

49. The effect of exercise-based interventions on health-related quality of life, physical and functional capacity, and side effects in older patients with colorectal cancer receiving medical antineoplastic treatments

The effect of exercise-based interventions on health-related quality of life, physical and functional capacity, and side effects in older patients with colorectal cancer receiving medical antineoplastic treatments Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD

2019 PROSPERO

50. The efficacy and safety of first-line systemic treatments among advanced colorectal cancer patients: a network meta-analysis of clinical trials

The efficacy and safety of first-line systemic treatments among advanced colorectal cancer patients: a network meta-analysis of clinical trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

51. Tumor-specific circulating cell-free DNA (ctDNA) and its clinical utility in predicting response to treatment or survival in patients with metastatic colorectal cancer: a systematic review

Tumor-specific circulating cell-free DNA (ctDNA) and its clinical utility in predicting response to treatment or survival in patients with metastatic colorectal cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

52. Oxaliplatin-based chemotherapy combined with Chinese herbal medicine under certain principle for colorectal cancer: a systematic review and meta-analysis

Oxaliplatin-based chemotherapy combined with Chinese herbal medicine under certain principle for colorectal cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

53. Synchronous renal cell carcinoma and colorectal cancer: a systematic review

Synchronous renal cell carcinoma and colorectal cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

54. Racial disparities in receipt of treatment among adult patients with colorectal cancer

Racial disparities in receipt of treatment among adult patients with colorectal cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

55. Cannabinoids can induce tumor reduction on experimental colorectal cancer models: A systematic review

Cannabinoids can induce tumor reduction on experimental colorectal cancer models: A systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

56. VEGF-A polymorphisms and clinical outcomes of bevacizumab-based chemotherapies in metastatic colorectal cancer: a systematic review and meta-analysis of observational studies

VEGF-A polymorphisms and clinical outcomes of bevacizumab-based chemotherapies in metastatic colorectal cancer: a systematic review and meta-analysis of observational studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

57. The impact of frailty on outcomes in elective colorectal cancer surgery, a systematic review

The impact of frailty on outcomes in elective colorectal cancer surgery, a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

58. The role of targeted therapies in colorectal cancer

The role of targeted therapies in colorectal cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

59. The role of Hepatic Arterial Infusion (HAI) in the treatment of adults with colorectal cancer (CRC) liver metastases

The role of Hepatic Arterial Infusion (HAI) in the treatment of adults with colorectal cancer (CRC) liver metastases Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

60. Cost comparisons of ambulatory chemotherapy using elastomeric infusion pumps to in-hospital conventional treatment in delivering 5FU continuous infusions for colorectal cancer patients: a systematic review

Cost comparisons of ambulatory chemotherapy using elastomeric infusion pumps to in-hospital conventional treatment in delivering 5FU continuous infusions for colorectal cancer patients: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO